BIOLOGICAL RESPONSE MODIFIERS IN AIDS MALIGNANCIES

罗斯威尔公园癌症研究所艾滋病相关肿瘤中心 （RPCI）是艾滋病相关患者的主要治疗中心。 纽约西部的恶性肿瘤 在泽尔医生的指导下 伯恩斯坦，该中心有一个快速增加的病人转诊期间， 近两年 再加上伯恩斯坦博士致力于 协议的制定和实施导致了出色的 研究所和多机构临床的患者增加 审判，与议定书持平，在某些情况下超过议定书的应计费用， 更多全国知名的中心 此外，两个I期临床 生物反应调节剂的试验已经在 一年来 一个广泛的淋巴细胞生物学实验室计划已经 由RPCI的Michael Caligiuri博士开发，专注于细胞因子和 细胞因子受体表达以及人类的特征 严重联合免疫缺陷小鼠中的淋巴瘤发生。 这项工作 已经转化为一系列I期和II期临床试验， 其中之一是由伯恩斯坦博士在艾滋病恶性肿瘤中完成的， 目前正在由CALGB为第二阶段合作研究开发。 的 研究所还在流式细胞术方面拥有杰出的专业知识， 设施，一直是至关重要的临床和实验室工作的博士。 伯恩斯坦和卡利久里。 随着患者人数的增加， 艾滋病恶性肿瘤的临床方案，强大的数据管理和 协议支持，以及基于实验室的想法的持续来源， 使用生物调节剂进行免疫调节以治疗免疫性疾病 缺陷，RPCI已经组建了一支强大的调查团队， 可能为相关研究提供独特的实验室资源， 在临床试验和患者设计方面的实质性创新 在艾滋病患者中快速完成此类试验的累积 临床试验联盟。

The Center for HIV-Related Malignancies at Roswell Park Cancer Institute (RPCI) is the main treatment center for patients with AIDS-associated malignancies in Western New York. Under the direction of Dr. Zale Bernstein, the Center has had a rapid increase in patient referrals during the past two years. This, combined with Dr. Bernstein's commitment to protocol development and implementation has resulted in outstanding accrual of patients to both Institute and multi-institutional clinical trials, on par and in some instances exceeding accrual to protocols at more nationally prominent centers. In addition, two phase I clinical trials with biologic response modifiers have been completed within the past year. An extensive laboratory program of lymphocyte biology has been developed by Dr. Michael Caligiuri at RPCI that focuses on cytokine and cytokine receptor expression, as well as the characterization of human lymphomagenesis in the severe combined immune deficient mouse. This work has been translated into a number of Phase I and Phase II clinical trials, one of which has been completed by Dr. Bernstein in AIDS malignancy and is now being developed by the CALGB for a Phase II cooperative study. The Institute also has outstanding expertise in Flow Cytometry, a core facility that has been vital to the clinical and laboratory work of Drs. Bernstein and Caligiuri, respectively. With excellent patient accrual to clinical protocols in AIDS malignancies, strong data management and protocol support, and a continual source of laboratory based ideas for immune modulation using biologic modifiers for therapy of immune deficiency, RPCI has assembled a strong team of investigators who are likely to provide unique laboratory resources for correlative studies, substantial innovation in the design of clinical trials and patient accrual for rapid completion of such trials within the AIDS Malignancies Clinical Trials Consortium.